Ann: PTX-100 receives U.S. FDA Fast Track Designation, page-77

Very good point about the benefits of PTX100 in regard to older patients, I remember Prof MP saying about a year ago he found PTX100 very friendly to work with and he was clearly impressed with PTX100's minimal risk of a side effects. In fact as l understand it there was patients that didn't have any side effects at all, please correct me if l am wrong. Under the circumstances if our patient results are of an acceptable standard for the FDA and our safety is on track as expected l believe we are unlikely to need Phase 3 to move towards Commercialisation.